Current status of adjuvant-targeted immunotherapy after radical surgery for hepatocellular carcinoma
10.12354/j.issn.1000-8179.2024.20240763
- VernacularTitle:肝细胞癌根治术后辅助靶向免疫治疗现状
- Author:
Fang YANG
1
;
Piao ZHENGRI
;
Zhang SONGNAN
Author Information
1. 延边大学附属医院肿瘤科(吉林省延吉市 133000)
- Keywords:
hepatocellular carcinoma(HCC);
targeted therapies;
immunotherapy;
recurrence;
high-risk factors;
postoperative adjuvant therapy
- From:
Chinese Journal of Clinical Oncology
2024;51(17):915-918
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related mortality.Although surgical resection,liver trans-plantation,and microwave ablation are key curative treatments,complications arise due to the insidious onset and rapid progression of HCC.At the time of diagnosis,microscopic metastasis may already be present in some patients,leading to a significant risk of recurrence,even after radical treatment.In recent years,systemic anti-tumor therapies,including targeted therapies and immune checkpoint inhibitors,have shown significant promise in reducing recurrence rates and prolonging survival.This review aims to integrate recent research findings to provide guidance for adjuvant therapy following radical surgery for HCC.
